DNA methyltransferase — Drug Target

All drugs that target DNA methyltransferase — marketed and clinical-stage. Includes 3 drug classes acting on this target.

Drug classes

Nucleoside Metabolic Inhibitor [EPC] · Hypomethylating agent · DNA methyltransferase inhibitor

Marketed (1)

• CEDAZURIDINE · Nucleoside Metabolic Inhibitor [EPC]
  Decitabine inhibits DNA methyltransferase, leading to DNA hypomethylation and cellular differentiation or apoptosis.

Phase 3 pipeline (1)

• Subcutaneous azacitidine · Otsuka Australia Pharmaceutical Pty Ltd · Hypomethylating agent · Oncology
  Azacitidine is a hypomethylating agent that works by inhibiting DNA methyltransferase enzymes, leading to increased expression of tumor suppressor genes.

Phase 2 pipeline (3)

• Azacitidine Injection [Vidaza] · Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias · Hypomethylating agent · Oncology
  Inhibits DNA methyltransferase
• Azacitidine associated with Lenalidomide · Assistance Publique - Hôpitaux de Paris · DNA methyltransferase inhibitor · Oncology
  Azacitidine is a DNA methyltransferase inhibitor.
• 5-Azacitidine · Shirley Ryan AbilityLab · Hypomethylating agent · Oncology
  Inhibits DNA methyltransferase

Phase 1 pipeline (1)

• ABT-348 and azacitidine · AbbVie (prior sponsor, Abbott) · Hypomethylating agent · Oncology
  AZA is a hypomethylating agent that targets DNA methyltransferase enzymes.